{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:18:22Z","timestamp":1793665102130,"version":"4.5.1"},"reference-count":18,"publisher":"BMJ","issue":"6","license":[{"start":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T00:00:00Z","timestamp":1750723200000},"content-version":"unspecified","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,6,11]]},"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>\n                    Although bispecific antibody (BsAb) treatment is a valuable therapeutic option for post chimeric antigen receptor (CAR)-T cell therapy against relapsed\/refractory large B-cell lymphoma, it remains to be clarified why it is still effective after intensive T-cell redirection therapy. Recently, the therapeutic potential of bystander CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells in the field of cancer immunotherapy have been discussed. In this study, we have shown a clinical impact where bystander CAR-negative CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells from a CAR-T cell product have a potential to augment immune responses of BsAb therapy through a case with relapsed diffuse large B-cell lymphoma after CD19 CAR-T cell therapy. T cells in a CAR-T-cell product dominantly showed central and effector memory T cells, and such T-cell phenotypes in peripheral blood significantly increased after CAR-T cell therapy. Furthermore, chronological T-cell receptor-\u03b2 repertoire analyses for both CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells and CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells suggested that product-derived bystander CAR\n                    <jats:sup>\u2212<\/jats:sup>\n                    CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cells successfully existed in a relapsed lymph node and expanded in the body after BsAb therapy. Further analyses are necessary, but our findings might help to explain the mechanisms and benefits of this sequential approach and strengthen the sequence of CAR-T cell therapy prior to BsAb therapy.\n                  <\/jats:p>","DOI":"10.1136\/jitc-2025-011690","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T21:16:21Z","timestamp":1750799781000},"page":"e011690","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Bystander CAR\n                    <sup>\u2212<\/sup>\n                    CD8\n                    <sup>+<\/sup>\n                    T cells in a CAR-T cell product can expand and enhance the antitumor effects of a bispecific antibody"],"prefix":"10.1136","volume":"13","author":[{"given":"Junichi","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-9435","authenticated-orcid":false,"given":"Tatsuya","family":"Konishi","sequence":"additional","affiliation":[{"name":"Division of Blood Transfusion and Cell Therapy, Ehime University Hospital, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Ehime University Hospital, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Maruta","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Nabe","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meika","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Doi","sequence":"additional","affiliation":[{"name":"Division of Blood Transfusion and Cell Therapy, Ehime University Hospital, Toon, Ehime, Japan"},{"name":"Department of Clinical Laboratory, Ehime University Hospital, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Takasuka","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Ehime University Hospital, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yamanouchi","sequence":"additional","affiliation":[{"name":"Division of Blood Transfusion and Cell Therapy, Ehime University Hospital, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-6144","authenticated-orcid":false,"given":"Toshiki","family":"Ochi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"},{"name":"Division of Immune Regulation, Proteo-Science Center, Ehime University, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[{"name":"Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,6,24]]},"reference":[{"key":"2026052722354379000_13.6.e011690.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026052722354379000_13.6.e011690.2","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"2026052722354379000_13.6.e011690.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01725"},{"key":"2026052722354379000_13.6.e011690.4","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"2026052722354379000_13.6.e011690.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206913"},{"key":"2026052722354379000_13.6.e011690.6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s43018-022-00335-8","article-title":"Bystander T cells in cancer immunology and therapy","volume":"3","author":"Meier","year":"2022","journal-title":"Nat Cancer"},{"key":"2026052722354379000_13.6.e011690.7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.2023022717","article-title":"B-cell-directed CAR T-cell therapy activates CD8+ cytotoxic CARneg bystander T cells in patients and nonhuman primates","volume":"144","author":"Kaminski","year":"2024","journal-title":"Blood"},{"key":"2026052722354379000_13.6.e011690.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101567","article-title":"IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy","volume":"5","author":"Lee","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026052722354379000_13.6.e011690.9","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-021-01791-1","article-title":"A single-chain antibody generation system yielding CAR-T cells with superior antitumor function","volume":"4","author":"Ochi","year":"2021","journal-title":"Commun Biol"},{"key":"2026052722354379000_13.6.e011690.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-00985-3"},{"key":"2026052722354379000_13.6.e011690.11","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.164.1.265"},{"key":"2026052722354379000_13.6.e011690.12","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20230903","article-title":"CAR-T cell manufacturing: Major process parameters and next-generation strategies","volume":"221","author":"Ayala Ceja","year":"2024","journal-title":"J Exp Med"},{"key":"2026052722354379000_13.6.e011690.13","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.22.012703.104702"},{"key":"2026052722354379000_13.6.e011690.14","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"2026052722354379000_13.6.e011690.15","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"key":"2026052722354379000_13.6.e011690.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022682"},{"key":"2026052722354379000_13.6.e011690.17","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01105-8","article-title":"Bispecific CAR-T cells targeting CD19\/20 in patients with relapsed or refractory B cell non-Hodgkin lymphoma: a phase I\/II trial","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026052722354379000_13.6.e011690.18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7100","article-title":"Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T)","volume":"42","author":"Bock","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-011690","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T05:36:05Z","timestamp":1779946565000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-011690"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6,24]]},"published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1136\/jitc-2025-011690"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-011690","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]}}}